{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:34:57Z","timestamp":1787841297297,"version":"build-2784847793"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3-4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T00:00:00Z","timestamp":1380240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Docetaxel belongs to the taxane family of anti-cancer drugs, which are commonly used in non-small cell lung cancers. They stabilize microtubules by preventing depolymerization, resulting in cell death. Pneumonitis is an uncommon side effect of docetaxel. We report a case of docetaxel induced hypersensitivity pneumonitis mimicking lymphangitic carcinomatosis in a patient with metastatic adenocarcinoma of the lung.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2013.08.005","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T18:32:08Z","timestamp":1380825128000},"page":"117-119","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Docetaxel-induced hypersensitivity pneumonitis mimicking lymphangitic carcinomatosis in a patient with metastatic adenocarcinoma of the lung"],"prefix":"10.4103","volume":"6","author":[{"given":"Asma","family":"Taj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"9","key":"10.1016\/j.hemonc.2013.08.005_b0005","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.1997.15.9.3149","article-title":"Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer","volume":"15","author":"Piccart","year":"1997","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hemonc.2013.08.005_b0010","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.1998.16.10.3426","article-title":"Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment","volume":"16","author":"Semb","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hemonc.2013.08.005_b0015","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.1996.14.5.1649","article-title":"Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study","volume":"14","author":"Kunitoh","year":"1996","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hemonc.2013.08.005_b0020","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hemonc.2013.08.005_b0025","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","article-title":"Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer","volume":"13","author":"Valero","year":"1995","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hemonc.2013.08.005_b0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1023\/A:1008377819875","article-title":"Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma","volume":"10","author":"Dunsford","year":"1999","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hemonc.2013.08.005_b0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1200\/JCO.1998.16.1.159","article-title":"Phase I study of docetaxel with concomitant thoracic radiation therapy","volume":"16","author":"Mauer","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hemonc.2013.08.005_b0040","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.1996.14.5.1649","article-title":"Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study","volume":"14","author":"Kunitoh","year":"1996","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hemonc.2013.08.005_b0045","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1054\/bjoc.2001.2071","article-title":"Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)","volume":"85","author":"Wang","year":"2001","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.hemonc.2013.08.005_b0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12094-007-0106-4","article-title":"Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment","volume":"9","author":"Grande","year":"2007","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.hemonc.2013.08.005_b0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10156-010-0058-4","article-title":"Severe interstitial pneumonitis associated with the administration of taxanes","volume":"16","author":"Nagata","year":"2010","journal-title":"J Infect Chemother"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387613000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387613000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201306030-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:01Z","timestamp":1787838541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201306030-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":11,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2013.08.005","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}